Expertise in
13
conditions

Dr. Rodney Rocconi

Oncology
University Pathology Associates PLLC
2500 N State St, 
Jackson, MS 
Offers Telehealth
Expertise in
13
conditions
University Pathology Associates PLLC
2500 N State St, 
Jackson, MS 

Overview

Rodney Rocconi is an Oncologist practicing medicine in Jackson, Mississippi.

Dr. Rocconi is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Cervical Cancer, and Hysterectomy.

He is actively involved in clinical research, co-authoring 78 peer reviewed articles and participating in 10 clinical trials.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in AL

Hospital Affiliations

University Of Mississippi Med Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

University Pathology Associates PLLC
2500 N State St, Jackson, MS 39216
Other Locations
Office
326 Commerce Center Dr Ste 2200, Ridgeland, MS 39157

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Terminated
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 24, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Enrollment Status: Completed
Publish Date: April 05, 2023
Intervention Type: Drug, Biological
Study Drugs: Vigil Tumor Cells, Atezolizumab
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drugs: Cabozantinib, Pembrolizumab
Study Phase: Phase 2
View 8 Less Clinical Trials

78 Total Publications

Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.
Journal: JCO precision oncology
Published: January 14, 2026
Similar Doctors
Expertise in
28
conditions
Dr. James Moore
Oncology
Expertise in
28
conditions
Dr. James Moore
Oncology

Premier Medical Group Of Mississippi LLC

501 Marshall St Ste G7, 
Jackson, MS 
 (1.9 miles away)
601-968-3238
Languages Spoken:
English
See accepted insurances

James Moore is an Oncologist practicing medicine in Jackson, Mississippi. Dr. Moore is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Vulvar Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Oophorectomy.

Expertise in
88
conditions
Dr. Tammy Young
Oncology
Expertise in
88
conditions
Dr. Tammy Young
Oncology

Jackson Oncology Associates

1227 N State St Ste 101, 
Jackson, MS 
 (1.9 miles away)
601-355-2485
Languages Spoken:
English
See accepted insurances

Tammy Young is an Oncologist practicing medicine in Jackson, Mississippi. Dr. Young is highly rated in 88 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Advanced Bronchoscopy.

Expertise in
66
conditions
Dr. Nicole Cleveland
Hematology | Oncology
Expertise in
66
conditions
Dr. Nicole Cleveland
Hematology | Oncology

Jackson Oncology Associates PLLC

2969 Curran Dr N Ste 200, 
Jackson, MS 
 (2.1 miles away)
601-974-5600
Languages Spoken:
English
See accepted insurances

Nicole Cleveland is a Hematologist and an Oncologist practicing medicine in Jackson, Mississippi. Dr. Cleveland is highly rated in 66 conditions, according to our data. Her clinical expertise encompasses Familial Colorectal Cancer, RUNX1 Familial Platelet Disorder, Hemangioma Thrombocytopenia Syndrome, Colorectal Cancer, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Rodney Rocconi

How do I make an appointment with Dr. Rodney Rocconi?

You can book an appointment with Dr. Rodney Rocconi by calling their office at 601-815-2005. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rodney Rocconi a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rodney Rocconi is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rodney Rocconi specialize in?

While Dr. Rodney Rocconi is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Rodney Rocconi participate in research or clinical trials?

Yes. Dr. Rodney Rocconi has published 78 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Rodney Rocconi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rodney Rocconi accept my insurance?

Dr. Rodney Rocconi accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 601-815-2005 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rocconi's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile